公开(公告)号：CA2562701A1

公开(公告)日：2005-12-01

申请号：CA2562701

申请日：2005-05-17

Applicant: CELLTECH R&D LTD

Inventor： BAKER TERENCE SEWARD ,  NORMAN TIMOTHY JOHN ,  MCKAY CATHERINE ,  PORTER JOHN ROBERT

IPC: C07K16/46 ,  A61K38/00 ,  A61K47/48 ,  C07D207/44 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention provides a compound consisting essentially of the following elements : one or more reactive groups ; and two or more cross- linked antibodies or fragments thereof ; characterised in that the or each reactive group is suitable for attaching an effector molecule but does not react with any of the antibodies or fragments thereof.

公开(公告)号：CA2417059A1

公开(公告)日：2002-02-07

申请号：CA2417059

申请日：2001-07-30

Applicant: CELLTECH R&D LTD

Inventor： HEAD JOHN CLIFFORD ,  MCKAY CATHERINE ,  PORTER JOHN ROBERT

IPC: A61K31/472 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61P1/04 ,  A61P3/10 ,  A61P7/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07D217/22 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12

Abstract: Squaric acid derivatives of formula (1) are described: wherein R1 is a hydrogen atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom o r group; Alk1 is an optionally substituted aliphatic chain; n is zero or the integer 1; R2 is a hydrogen atom or an optionally substituted heteroaliphati c, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group; Alk is a chain (a), (b), (c) or (d)in which R is a carboxylic acid (-CO2H) or a derivative or biostere thereof; Ar2 is an optionally substituted aromatic or heteroaromati c linking group; L2 is a covalent bond or a linker atom or group; R16 is the group -L3(Alk2)tL4R20 in which L3 and L4 which may be the same or different is each a covalent bond or a linker atom or group, t is zero or the integer 1, Alk2 is an optionally substituted aliphatic or heteroaliphatic chain and R20 is an optionally substituted aromatic or heteroaromatic group. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders including the inappropriate growth or migration of cells.